rmc-4630
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 29, 2018 (NCT03634982)
Timeline
Indications
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05054725 | Phase 2 | Nov 30, 2021 | Amgen, Revolution Medicines, Inc., Sanofi |
| NCT04916236 | Phase 1 | Oct 31, 2021 | Lustgarten Foundation, Netherlands Cancer Institute |
| NCT03989115 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2019 | Revolution Medicines, Inc., Sanofi |
| NCT03634982 | Phase 1 | Sep 29, 2018 | Revolution Medicines, Inc., Sanofi |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Revolution Medicines, Inc. | For profit | 3 | 3 | 2 | 2018 |
| Sanofi | For profit | 3 | 0 | 2 | 2018 |
| Amgen | For profit | 1 | 0 | 1 | 2021 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1